Skip to main content

Eli Lilly and Company Mounjaro revenue

  • LLY · NYSE
  • Pharmaceuticals
  • S&P 500
$1443.50+1.14%Close 13 Nov 2026 · Market value $1.36T

Mounjaro revenue at Eli Lilly and Company came to $5.0B for the quarter to 30 Sep 2026, up 40.8% from a year earlier.

As Eli Lilly and Company reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 29 Oct 2026.

By quarter

$2.1BDec 2023$1.5BMar 2024$2.4BJun 2024$2.4BSep 2024$2.6BDec 2024$2.7BMar 2025$3.3BJun 2025$3.6BSep 2025$4.1BDec 2025$4.2BMar 2026$4.8BJun 2026$5.0BSep 2026
Eli Lilly and Company Mounjaro revenue, every reported period
Period endingMounjaro revenueChange on a yearFiled
30 Sep 2026$5.0Bup 40.8%29 Oct 2026
30 Jun 2026$4.8Bup 45.1%5 Aug 2026
31 Mar 2026$4.2Bup 59.3%30 Apr 2026
31 Dec 2025$4.1Bup 57.5%12 Feb 2026
30 Sep 2025$3.6Bup 48.9%30 Oct 2025
30 Jun 2025$3.3Bup 36.8%7 Aug 2025
31 Mar 2025$2.7Bup 74.7%1 May 2025
31 Dec 2024$2.6Bup 25.0%19 Feb 2025
30 Sep 2024$2.4Bup 86.7%30 Oct 2024
30 Jun 2024$2.4Bup 163.6%8 Aug 2024
31 Mar 2024$1.5Bup 183.4%30 Apr 2024
31 Dec 2023$2.1B—21 Feb 2024
30 Sep 2023$1.3Bup 1212.4%2 Nov 2023
30 Jun 2023$915.7M—8 Aug 2023
31 Mar 2023$536.4M—27 Apr 2023
30 Sep 2022$97.3M—1 Nov 2022
30 Jun 2022$12.6M—4 Aug 2022
31 Mar 2022$0—29 Apr 2022
30 Sep 2021$0—27 Oct 2021

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Eli Lilly and Company: Cardiometabolic Health revenue · Zepbound revenue · Oncology revenue · Verzenio revenue · Immunology revenue · Jardiance revenue · Trulicity revenue · Taltz revenue · Neuroscience revenue · United States revenue · Outside U.S. revenue · Europe revenue · Rest of world revenue · China revenue · Japan revenue · financial statements

Every KPI and segment of LLY, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.